1[1]Verheij M, Bartelink H. Radiation-induced apoptosis[J]. Cell Tissue Res,2000, 301 (1) : 133-142.
2[2]Zeng M, Narayanan L, Xu XS, et al. Ionizing radiation-induced apoptosis via separate Pms2-and p53-dependent pathways[J]. Cancer Res, 2000,60(17) :4889-4893.
3[3]Michael Weller. Predicting response to cancer chemotherapy: the role of P43[J]. Cell Tissue Res, 1998,292:435-445.
4[4]Oconnor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents[J]. Cancer Res, 1997,57:4285-4300.
5[5]Debemardis D, Sire EG, DE Feudis P, et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res, 1997,57 : 870-874.
6[6]Pestell KE, Hobbs SM, Titley, JC, et al. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line[J]. Mol Pharmacel,2000,57(3) :503-511.
7[7]Sato S,Kigawa J,Minagawa Y,et al. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma [J]. Cancer, 1999, 86 (7) : 1307-1313.
8[8]Irie T, Kigawa J, Minagawa Y, et al. Alteration of a p53 gene status affects outcome of patients with recurrent ovarian cancer[J]. Oncology, 2000,58(3) :237-241.
9[9]Gadducci A,Cianci C,Cosio S,et al.p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paditaxel-based regimen[J]. Anticancer Res, 2000,20(6C) : 4793-4799.
10[10]Lavarino C,Pilotti S, Oggiormi M,et al.p53 gene status and response to platinum/paclitaxd-based chemotherapy in advanced ovarian carcinoma [J]. J Clin Oncol,2000,18(23) :3936-3945.
